Enanta Pharmaceuticals | ENTA - Capitale Sociale E Riserve





Capitale Sociale E Riserve Cambiamento Data
AbbVie USD -5.94B 721M 2026-06
Amgen USD 11.69B 2.5B 2026-06
Anika Therapeutics USD 137.28M 3.38M 2026-06
Arrowhead Research USD 465.53M 148.45M 2026-06
AstraZeneca USD 50.3B 2.96B 2026-06
BioCryst Pharmaceuticals USD -454.29M 99.55M 2026-06
Biogen USD 18.85B 196.3M 2026-06
Bristol-Myers Squibb USD 22.32B 2.25B 2026-06
Enanta Pharmaceuticals USD 126.59M 61.87M 2025-12
Gilead Sciences USD 11.74B 11.77B 2026-06
GlaxoSmithKline GBP 17.64B 223M 2026-06
Halozyme Therapeutics USD 143.54M 76.09M 2026-06
Heron Therapeutics USD 6.91M 2.23M 2026-06
Immunic USD 151.23M 157.91M 2026-03
Incyte USD 6.34B 721.58M 2026-06
Insmed USD 757.49M 52.64M 2026-06
Ionis Pharmaceuticals USD 439.74M 51.68M 2026-06
J&J USD 84.97B 3.78B 2026-06
Karyopharm Therapeutics USD -265.65M 27.28M 2026-03
Ligand Pharmaceuticals USD 967.52M 29.81M 2026-06
Merck USD 41.93B 3.94B 2026-06
Neurocrine Biosciences USD 3.69B 286.2M 2026-06
Novartis USD 41.95B 3.02B 2026-06
Novavax USD -190.71M 45.94M 2026-06
Pfizer USD 85.19B 4.91B 2026-06
PTC Therapeutics USD -165.36M 15.1M 2026-06
Roche Holding CHF 32.69B 1.11B 2026-06
Sarepta Therapeutics USD 1.53B 22.7M 2026-06
Vertex Pharmaceuticals USD 20.25B 886M 2026-06